Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Gynecology

Free Subscription Articles published in Lancet Retrieve available abstracts of 74 articles: HTML format

Single Articles

March 2023
1. LEDERMAN S, Ottery FD, Cano A, Santoro N, et al
   Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
   Lancet. 2023 Mar 13:S0140-6736(23)00085-5. doi: 10.1016/S0140-6736(23)00085.
   PubMed     Abstract available
   
   
   
2. PRAGUE JK
   Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms.
   Lancet. 2023 Mar 13:S0140-6736(23)00353-7. doi: 10.1016/S0140-6736(23)00353.
   PubMed    
   
   
   
3. MORLEY LC, Sparey C, Wijeratne D, Turner K, et al
   A planned caesarean hysterectomy for placenta accreta spectrum at 35 weeks of gestation: antenatal identification and a multidisciplinary approach to manage an increasing condition.
   Lancet. 2023;401:856-857.
   PubMed    
   
   
   
4. CLUVER C, de Groot C, Mol BW, Murphy KE, et al
   The need for appropriate language in the debate on medicalisation of pregnancy.
   Lancet. 2023;401:818-819.
   PubMed    
   
   
   
5. KAKURU A, Jagannathan P
   Can we reduce malaria in pregnancy and improve birth outcomes?
   Lancet. 2023 Mar 10:S0140-6736(23)00101-0. doi: 10.1016/S0140-6736(23)00101.
   PubMed    
   
   
   
6. MADANITSA M, Barsosio HC, Minja DTR, Mtove G, et al
   Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlle
   Lancet. 2023 Mar 10:S0140-6736(22)02535-1. doi: 10.1016/S0140-6736(22)02535.
   PubMed     Abstract available
   
   
   
7. HAWKES S, Kedia S, Odunga S, Dahal M, et al
   From flowers to menstrual-flow trackers: the corporatisation of women's equality and wellbeing.
   Lancet. 2023 Mar 7:S0140-6736(23)00456-7. doi: 10.1016/S0140-6736(23)00456.
   PubMed    
   
   
   February 2023
8. MURRAY CJL
   A systematic analysis points in the wrong direction for cervical cancer elimination - Author's reply.
   Lancet. 2023;401:555-556.
   PubMed    
   
   
   
9. JACKSON A
   A systematic analysis points in the wrong direction for cervical cancer elimination.
   Lancet. 2023;401:555.
   PubMed    
   
   
   
10. DUGOFF L
    The use of cell-free DNA technology in pregnancy loss.
    Lancet. 2023 Feb 1:S0140-6736(23)00182-4. doi: 10.1016/S0140-6736(23)00182.
    PubMed    
    
    
    
11. SCHLAIKJAER HARTWIG T, Ambye L, Gruhn JR, Petersen JF, et al
    Cell-free fetal DNA for genetic evaluation in Copenhagen Pregnancy Loss Study (COPL): a prospective cohort study.
    Lancet. 2023 Feb 1:S0140-6736(22)02610-1. doi: 10.1016/S0140-6736(22)02610.
    PubMed     Abstract available
    
    
    
12. HORNE AW, Tong S, Moakes CA, Middleton LJ, et al
    Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial.
    Lancet. 2023 Feb 1:S0140-6736(22)02478-3. doi: 10.1016/S0140-6736(22)02478.
    PubMed     Abstract available
    
    
    
13. SONALKAR S, Gilmore E
    A fresh look at treatment for ectopic pregnancy.
    Lancet. 2023 Feb 1:S0140-6736(23)00181-2. doi: 10.1016/S0140-6736(23)00181.
    PubMed    
    
    
    January 2023
14. ELLINGTON S, Jatlaoui TC
    COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy.
    Lancet. 2023 Jan 17:S0140-6736(22)02613-7. doi: 10.1016/S0140-6736(22)02613.
    PubMed    
    
    
    
15. VILLAR J, Soto Conti CP, Gunier RB, Ariff S, et al
    Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study.
    Lancet. 2023 Jan 17:S0140-6736(22)02467-9. doi: 10.1016/S0140-6736(22)02467.
    PubMed     Abstract available
    
    
    December 2022
16. SHEIKH J, Allotey J, Kew T, Fernandez-Felix BM, et al
    Effects of race and ethnicity on perinatal outcomes in high-income and upper-middle-income countries: an individual participant data meta-analysis of 2 198 655 pregnancies.
    Lancet. 2022;400:2049-2062.
    PubMed     Abstract available
    
    
    November 2022
17. SAITO M, McGready R, Tinto H, Rouamba T, et al
    Pregnancy outcomes after first-trimester treatment with artemisinin derivatives versus non-artemisinin antimalarials: a systematic review and individual patient data meta-analysis.
    Lancet. 2022 Nov 25:S0140-6736(22)01881-5. doi: 10.1016/S0140-6736(22)01881.
    PubMed     Abstract available
    
    
    
18. SLUTSKER L, Leke RGF
    First-trimester use of ACTs for malaria treatment in pregnancy.
    Lancet. 2022 Nov 25:S0140-6736(22)02166-3. doi: 10.1016/S0140-6736(22)02166.
    PubMed    
    
    
    
19. OLAJIDE N, Robb K, Niedzwiedz C, Jani B, et al
    Cervical cancer risk factors in eight west African countries: cross-sectional analysis of the demographic and health survey 2017-20.
    Lancet. 2022;400 Suppl 1:S68.
    PubMed     Abstract available
    
    
    
20. ANDREAE G, Scott S, Nguyen G, Bell Z, et al
    Food insecurity among pregnant women living in high-income countries: a systematic review.
    Lancet. 2022;400 Suppl 1:S17.
    PubMed     Abstract available
    
    
    October 2022
21. DASHRAATH P, Thong WSE, Ang M, Lee YM, et al
    Interferon shrinks spleen in pregnant patient with myeloproliferative neoplasm.
    Lancet. 2022;400:e11.
    PubMed    
    
    
    
22. BAUD D, Nielsen-Saines K, Mattar C, Musso D, et al
    Monkeypox exposure during pregnancy: what does UK public health guidance advise? - Authors' reply.
    Lancet. 2022;400:1509-1510.
    PubMed    
    
    
    
23. ADLER H, Taggart R
    Monkeypox exposure during pregnancy: what does UK public health guidance advise?
    Lancet. 2022;400:1509.
    PubMed    
    
    
    
24. VAN LENNEP JER, Nerenberg KA
    Delivering evidence to prevent recurrent venous thromboembolism in pregnancy.
    Lancet. 2022 Oct 28. pii: S0140-6736(22)02030.
    PubMed    
    
    
    
25. BISTERVELS IM, Buchmuller A, Wiegers HMG, Ni Ainle F, et al
    Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial.
    Lancet. 2022 Oct 28. pii: S0140-6736(22)02128.
    PubMed     Abstract available
    
    
    
26. HODGETTS MORTON V, Toozs-Hobson P, Moakes CA, Middleton L, et al
    Monofilament suture versus braided suture thread to improve pregnancy outcomes after vaginal cervical cerclage (C-STICH): a pragmatic randomised, controlled, phase 3, superiority trial.
    Lancet. 2022;400:1426-1436.
    PubMed     Abstract available
    
    
    
27. GLYDE T
    LGBTQIA+ menopause: room for improvement.
    Lancet. 2022 Oct 18. pii: S0140-6736(22)01935.
    PubMed    
    
    
    
28. KHALIL A, Samara A, Ladhani S, O'Brien P, et al
    Monkeypox and pregnancy: time for global surveillance and prevention strategies.
    Lancet. 2022;400:1193.
    PubMed    
    
    
    September 2022
29. DONNEZ J, Taylor HS, Stewart EA, Bradley L, et al
    Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
    Lancet. 2022;400:896-907.
    PubMed     Abstract available
    
    
    
30. DE LANGE ME, Huirne JAF
    Linzagolix: an oral gonadotropin-releasing hormone receptor antagonist treatment for uterine fibroid-associated heavy menstrual bleeding.
    Lancet. 2022;400:866-867.
    PubMed    
    
    
    August 2022
31. ENDLER M, Petro G, Gemzell Danielsson K, Grossman D, et al
    A telemedicine model for abortion in South Africa: a randomised, controlled, non-inferiority trial.
    Lancet. 2022;400:670-679.
    PubMed     Abstract available
    
    
    
32. WINIKOFF B, Lohr PA
    Randomised trials of medical abortion provide some but not all the answers.
    Lancet. 2022;400:638-639.
    PubMed    
    
    
    
33. ROBERTS SL, Kendall GS, Edwards S, Pandya P, et al
    Screening policies for cytomegalovirus in pregnancy in the era of antivirals.
    Lancet. 2022;400:489-490.
    PubMed    
    
    
    July 2022
34. HAAKENSTAD A, Angelino O, Irvine CMS, Bhutta ZA, et al
    Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet. 2022;400:295-327.
    PubMed     Abstract available
    
    
    
35. PRADHAN MR
    Contraceptive mix and informed choice.
    Lancet. 2022;400:255-257.
    PubMed    
    
    
    
36. JAFFE S
    "Chaos" for patients and providers after US abortion ruling.
    Lancet. 2022;400:85-86.
    PubMed    
    
    
    
37. HIAM L, Mateescu I, Spiegel P
    Improving access to contraception and abortion in Romania in the context of the conflict in Ukraine.
    Lancet. 2022 Jul 8. pii: S0140-6736(22)01275.
    PubMed    
    
    
    
38. JAFFE S
    Federal abortion rights end, but not legal challenges.
    Lancet. 2022;400:13-14.
    PubMed    
    
    
    June 2022
39. DASHRAATH P, Nielsen-Saines K, Mattar C, Musso D, et al
    Guidelines for pregnant individuals with monkeypox virus exposure.
    Lancet. 2022 Jun 21. pii: S0140-6736(22)01063.
    PubMed    
    
    
    
40. GIUDICE LC, As-Sanie S, Arjona Ferreira JC, Becker CM, et al
    Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2).
    Lancet. 2022;399:2267-2279.
    PubMed     Abstract available
    
    
    
41. SARASWAT L, Bhattacharya S
    Relugolix combination therapy for endometriosis pain.
    Lancet. 2022;399:2244-2245.
    PubMed    
    
    
    
42. HOLT E
    Poland to introduce controversial pregnancy register.
    Lancet. 2022;399:2256.
    PubMed    
    
    
    
43. THE LANCET
    Attitudes towards menopause: time for change.
    Lancet. 2022;399:2243.
    PubMed    
    
    
    
44. O'BRIEN E, Rich M
    Obstetric violence in historical perspective.
    Lancet. 2022;399:2183-2185.
    PubMed    
    
    
    
45. REED SD, Zhou X, Ichikawa L, Gatz JL, et al
    Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study.
    Lancet. 2022;399:2103-2112.
    PubMed     Abstract available
    
    
    
46. BARTZ D
    Incidence of perforation with intrauterine devices.
    Lancet. 2022;399:2076-2077.
    PubMed    
    
    
    May 2022
47. SCHAEDEL Z, Rymer J
    Menopause care and over the counter vaginal oestradiol.
    Lancet. 2022 May 31. pii: S0140-6736(22)00952.
    PubMed    
    
    
    
48. JARDINE J, Harris T, Khalil A, van der Meulen J, et al
    Adverse pregnancy outcomes: biological essentialism versus embodied biology - Authors' reply.
    Lancet. 2022;399:2014.
    PubMed    
    
    
    
49. RAVI K, Janiak E
    Adverse pregnancy outcomes: biological essentialism versus embodied biology.
    Lancet. 2022;399:2013-2014.
    PubMed    
    
    
    
50. SASIENI P, Castanon A
    HPV vaccination and cervical cancer screening - Authors' reply.
    Lancet. 2022;399:1940.
    PubMed    
    
    
    
51. BEWLEY S
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939.
    PubMed    
    
    
    
52. KAMAMOTO S, Murayama A, Hamaki T, Kusumi E, et al
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939-1940.
    PubMed    
    
    
    
53. JAFFE S
    Health organizations fear effects of US abortion ruling.
    Lancet. 2022;399:1854.
    PubMed    
    
    
    
54. VOSS FO, van Beurden M, Jordanova ES
    Topical imiquimod as first-line treatment for vulvar intraepithelial neoplasia.
    Lancet. 2022;399:1755-1757.
    PubMed    
    
    
    
55. TRUTNOVSKY G, Reich O, Joura EA, Holter M, et al
    Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial.
    Lancet. 2022;399:1790-1798.
    PubMed     Abstract available
    
    
    
56. DASHRAATH P, Chen K, Htet ZW, Chan SY, et al
    Pre-eclampsia with paradoxical polyuria: diabetes insipidus in pregnancy.
    Lancet. 2022;399:1809.
    PubMed    
    
    
    April 2022
57. MAKONI M
    Hope for access to abortion in Kenya.
    Lancet. 2022;399:1456.
    PubMed    
    
    
    
58. CROSBIE EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, et al
    Endometrial cancer.
    Lancet. 2022;399:1412-1428.
    PubMed     Abstract available
    
    
    March 2022
59. BOOTH A
    Activists welcome Colombia's decriminalisation of abortion.
    Lancet. 2022;399:899.
    PubMed    
    
    
    
60. MANCA T, Baylis F, Munoz FM, Top KA, et al
    Prioritise research on vaccines for pregnant and breastfeeding women.
    Lancet. 2022;399:890-893.
    PubMed    
    
    
    February 2022
61. PASHANKAR R, Prabulos AM, Feder HM Jr
    A woman pregnant with twins has fever, haemolysis, and thrombocytopenia caused by babesiosis: could be confused with HELLP syndrome.
    Lancet. 2022;399:e10.
    PubMed    
    
    
    
62. KALAFAT E, Magee LA, von Dadelszen P, Heath P, et al
    COVID-19 booster doses in pregnancy and global vaccine equity.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00166.
    PubMed    
    
    
    
63. GERSHENSON DM, Miller A, Brady WE, Paul J, et al
    Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.
    Lancet. 2022;399:541-553.
    PubMed     Abstract available
    
    
    
64. BLAGDEN SP
    Targeting MAPK in recurrent, low-grade serous ovarian cancer.
    Lancet. 2022;399:499-501.
    PubMed    
    
    
    
65. CERDEIRA AS, Ismail L, Moore N, George B, et al
    Retroperitoneal leiomyomatosis: a benign outcome of power morcellation with potentially serious consequences.
    Lancet. 2022;399:554.
    PubMed    
    
    
    January 2022
66. HUG L, You D, Blencowe H, Moran AC, et al
    Strengthening the reporting of stillbirths globally - Authors' reply.
    Lancet. 2022;399:142.
    PubMed    
    
    
    
67. DAS AM, Janardhanan R
    Strengthening the reporting of stillbirths globally.
    Lancet. 2022;399:141.
    PubMed    
    
    
    
68. JOOS O, Swiney C, Sferrazza L
    Strengthening the reporting of stillbirths globally.
    Lancet. 2022;399:140-141.
    PubMed    
    
    
    December 2021
69. JAFFE S
    US Supreme Court expected to weaken abortion rights.
    Lancet. 2021;398:2137-2138.
    PubMed    
    
    
    November 2021
70. SANSON C, Majer M, Pautier P, Gouy S, et al
    Unexplained uterine atrophy following neoadjuvant chemotherapy in fertility sparing management of cervical cancer.
    Lancet. 2021;398:e17.
    PubMed    
    
    
    
71. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
    The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
    PubMed     Abstract available
    
    
    
72. CRUICKSHANK ME, Grigore M
    Cervical cancers avoided by HPV immunisation.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02396.
    PubMed    
    
    
    
73. JARDINE J, Walker K, Gurol-Urganci I, Webster K, et al
    Adverse pregnancy outcomes attributable to socioeconomic and ethnic inequalities in England: a national cohort study.
    Lancet. 2021 Nov 1. pii: S0140-6736(21)01595.
    PubMed     Abstract available
    
    
    October 2021
74. THE LANCET
    Abortion bans in the USA harm health equity.
    Lancet. 2021;398:1461.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: